Alison Yoder, MD MPH
Department of Radiation Oncology, Division of Radiation Oncology
About Alison Yoder
Dr. Alison Yoder is an Assistant Professor in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center. Before her appointment as faculty, she received her MD at Baylor College of Medicine and MPH at the University of Texas Health Science Center at Houston, followed by residency training at MD Anderson Cancer Center.
In her appointment to the Melanoma & Sarcoma Radiation Oncology section she specializes in the treatment of bone and soft tissue sarcomas, melanomas, and other non-melanomatous skin malignancies. She has clinical expertise in a variety of standard and specialized radiation treatment modalities including intensity modulated radiation therapy (IMRT/VMAT), proton therapy, stereotactic body radiation therapy (SBRT), image-guided radiotherapy (IGRT), MRI-guided radiation therapy, and 3D conformal radiation (photons/electrons).
Her research is focused on patient-reported outcomes and quality of life both during and after the completion of radiation treatment. She has received funding from extramural sources including the American College of Radiation Oncology (ACRO). Her research has been presented at international conferences and published across a variety of peer-reviewed medical journals.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2019 | Baylor College of Medicine, Houston, TX, US, Doctor of Medicine |
| 2019 | University of Texas Health Science Center at Houston School of Public Health, Houston, TX, US, Epidemiology, Master of Public Health |
| 2011 | Washington University in St. Louis, St. Louis, MO, US, Chemical Engineering, Bachelor of Science |
Postgraduate Training
| 2020-2024 | Resident, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2019-2020 | Intern, Transitional Medicine, University of Texas Health Science Center at Houston McGovern School of Medicine, Houston, TX |
Experience & Service
Other Appointments/Responsibilities
Run Plant Engineer, The Dow Chemical Company, Lake Jackson, TX, 2011 - 2014
Honors & Awards
| 2024 | Daniel Benedict Gazan Endowed Fellowship Research Excellence Award for Sarcoma Research, The University of Texas MD Anderson |
| 2024 | Resident Educator of the Year, The University of Texas MD Anderson |
| 2023 | Connective Tissue Oncology Society Young Investigator Award, Connective Tissue Oncology Society |
| 2023 | Mary Fletcher Heart of Caring Award, The University of Texas MD Anderson |
| 2023 | Trainee Research Day – Oral Presentation Award in the Cancer Survivorship Research Category, The University of Texas MD Anderson |
| 2022 | ACRO Resident Seed Grant Award Winner, ACRO |
| 2022 | ROC-STaR Award: Radiation Oncology Commendations and Recognition, The University of Texas MD Anderson |
| 2021 | ROC-STaR: Radiation Oncology Commendations and Recognition, The University of Texas MD Anderson |
| 2019 | Baroch A. Brody Award in Medical Ethics, Baylor College of Medicine |
| 2018 | Alpha Omega Alpha Membership, Alpha Omega Alpha |
| 2018 | Baylor College of Medicine Department of Radiation Oncology Award, Baylor College of Medicine |
| 2018 | "Best of ASTRO Abstract", ASTRO |
Selected Publications
Peer-Reviewed Articles
- Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Characterization of lymphopenia and correlating the risk of cytopenias with dose and BM volume irradiated in aggressive B-cell lymphoma patients bridged with radiation therapy for CAR-T cell therapy. Int J Radiat Oncol Biol Phys None(None):None, 2024. PMID: 39303997.
- Yoder AK, Farooqi A, Mitra D, Livingston JA, Araujo DM, Sturgis EM, Goepfert R, Bishop AJ, Guadagnolo BA. Outcomes for Patients With Head and Neck Sarcoma Treated Curatively With Radiation Therapy and Surgery. Pract Radiat Oncol 14(5):e373-e382, 2024. PMID: 38851534.
- Yoder AK, Xu T, Youssef P, DeSnyder S, Marqueen KE, Isales L, Lin R, Smith BD, Woodward WA, Stauder MC, Strom EA, Aldrich MB, Shaitelman SF. Association Between Symptom Burden and Early Lymphatic Abnormalities After Regional Nodal Irradiation for Breast Cancer. Pract Radiat Oncol 14(3):e180-e189, 2024. PMID: 37914083.
- Farooqi AS, Yoder AK, Lin HY, Pasalic D, Erasmus J, Betancourt S, Wernz C, Mitra D, Zarzour MA, Somaiah N, Conley A, Ratan R, Livingston A, Araujo DM, Roland C, Scally C, Keung E, Gandhi SN, Ashleigh Guadagnolo B, Nguyen QN, Bishop AJ. SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys 118(4):971-978, 2024. PMID: 37914142.
- Yoder AK, Lakomy DS, Wu J, Andring LM, Corrigan KL, Fellman B, Jhingran A, Klopp AH, Colbert LE, Soliman PT, Frumovitz MM, Peterson SK, Lin LL. Comparing long-term sexual dysfunction across different uterine cancer treatment modalities. Brachytherapy 23(1):1-9, 2024. PMID: 37914588.
- Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs. Front Oncol 14(None):1447020, 2024. PMID: 39324011.
- Salzillo TC, Dresner MA, Way A, Wahid KA, McDonald BA, Mulder S, Naser MA, He R, Ding Y, Yoder A, Ahmed S, Corrigan KL, Manzar GS, Andring L, Pinnix C, Stafford RJ, Mohamed ASR, Christodouleas J, Wang J, Fuller CD. Development and implementation of optimized endogenous contrast sequences for delineation in adaptive radiotherapy on a 1.5T MR-linear-accelerator: a prospective R-IDEAL stage 0-2a quantitative/qualitative evaluation of in vivo site-specific quality-assurance using a 3D T2 fat-suppressed platform for head and neck cancer. J Med Imaging (Bellingham) 10(6):065501, 2023. PMID: 37937259.
- Andring LM, Abu-Gheida I, Bathala T, Yoder AK, Manzar GS, Maldonado JA, Frank SJ, Choi S, Nguyen QN, Hoffman K, McGuire SE, Mok H, Aparicio A, Chapin BF, Tang C. Definitive local therapy for T4 prostate cancer associated with improved local control and survival. BJU Int 132(3):307-313, 2023. PMID: 37057728.
- Yoder AK, Farooqi AS, Wernz C, Subramaniam A, Ravi V, Goepfert R, Sturgis EM, Mitra D, Bishop AJ, Guadagnolo BA. Outcomes after definitive treatment for cutaneous angiosarcomas of the face and scalp: Reevaluating the role of surgery and radiation therapy. Head Neck 45(8):1943-1951, 2023. PMID: 37272774.
- Yoder AK, Dong E, Yu X, Echeverria A, Sharma S, Montealegre J, Ludwig MS. Effect of Quality of Life on Radiation Adherence for Patients With Cervical Cancer in an Urban Safety Net Health System. Int J Radiat Oncol Biol Phys 116(1):182-190, 2023. PMID: 36228745.
- Yoder AK, Lakomy DS, Wu J, Andring LM, Fellman B, Colbert LE, Jhingran A, Klopp AH, Soliman P, Peterson SK, Lin LL. Impact of Treatment Modality on Quality of Life Among Uterine Cancer Survivors. Clin Oncol (R Coll Radiol) 35(2):e215-e226, 2023. PMID: 36494250.
- Lakomy DS, Yoder AK, Wu J, Hernandez M, Ayoola-Adeola M, Jhingran A, Klopp A, Soliman P, Peterson SK, Lin LL. Impact of treatment modality on pelvic floor dysfunction among uterine cancer survivors. Int J Gynecol Cancer None(None):None, 2022. PMID: 35680139.
- Corrigan KL, Yoder A, De B, Lin L, Jhingran A, Joyner MM, Eifel PJ, Colbert LE, Lu KH, Klopp AH. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. Gynecol Oncol 164(3):550-557, 2022. PMID: 34974906.
- Shi F, Yoder AK, Mach C, Dalwadi S, Anderson ML, Hall TR, Ludwig MS. Impact of hematologic toxicities during concurrent chemoradiation for cervical cancer. Obstet Gynecol Sci 65(2):176-187, 2022. PMID: 35189679.
- Andring L, Yoder A, Pezzi T, Tang C, Kumar R, Mahmood U, Walker GV. PSA: Declining utilization of prostate brachytherapy. Brachytherapy 21(1):6-11, 2022. PMID: 34420862.
- Yoder AK, Lakomy DS, Dong Y, Raychaudhury S, Royse K, Hartman C, Richardson P, White DL, Kramer JR, Lin LL, Chiao E. The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study. BMC Cancer 21(1):776, 2021. PMID: 34225709.
- Boyce-Fappiano D, Bedrosian I, Shen Y, Lin H, Gjyshi O, Yoder A, Shaitelman SF, Woodward WA. Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. NPJ Breast Cancer 7(1):87, 2021. PMID: 34226566.
- Elhammali A, Milgrom SA, Amini B, Gunther JR, Yoder A, Ludmir EB, Moon B, Weber DM, Thomas SK, Garg N, Manasanch EE, Patel KK, Orlowski RZ, Lee HC, Bird JE, Satcher R, Lin P, Pinnix CC, Dabaja BS. Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. Clin Lymphoma Myeloma Leuk 19(8):e465-e469, 2019. PMID: 31133526.
- Elhammali A, Blanchard P, Yoder A, Liao Z, Zhang X, Ronald Zhu X, Allen PK, Jeter M, Welsh J, Nguyen QN. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol 136(None):136-142, 2019. PMID: 31015115.
- Hanania AN, Myers P, Yoder AK, Bulut A, Henry Yu Z, Eraj S, Bowers J, Bonnen MD, Echeverria A, Hall TR, Anderson ML, Ludwig M. Inversely and adaptively planned interstitial brachytherapy: A single implant approach. Gynecol Oncol 152(2):353-360, 2019. PMID: 30449720.
- Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. PMID: 30360985.
Other Articles
- Yoder AK, Gunther JR, Milgrom SA, Pham M, Hancock D, McSpadden K, Garcia J, Mirkovic D, Dabaja BS, Pinnix CC Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. Pract Radiat Oncol 9(3):147-152, 2019. PMID: 30708131.
- Waheed NL, Yoder AK, Van Wyhe RD, Carpenter SL Stereotactic Body Radiation Therapy for Prostate Cancer: An Institutional Experience Using MRI-guided Treatment Planning. Cureus 10(5):e2590, 2018. PMID: 30009104.
Abstracts
- Arifin A, Jerez O, Keatts S, Salem AFM, Farooqi A, Bishop AJ, Yoder AK, Goepfert RP, Weiser R, Amaria R, McQuade J, Ross MI, Guadagnolo BA, Mitra D. Adjuvant Primary Site Radiation Therapy for Melanoma in the Immunotherapy Era. Int J Radiat Oncol Biol Phys 120(2):S179-180, 2024. PMID: None.
Book Chapters
- Yoder A, Ning M, Lin LL. Cancer Radiotherapy – General Considerations and Human Biology. In: Locoregional Radionuclide Cancer Therapy. None. Springer, None, 2022.
- Yoder A. Supranuclear Disorders of Gaze. In: Clinical Pathways in Neuro-Ophthalmology. 3rd. Thieme, None, 2018.
- Yoder A, Mitra D, Guadagnolo BA. Melanoma. In: Pocket Radiation Oncology. 2nd. None, None.
- Yoder A, Bishop AJ, Guadagnolo BA. Soft Tissue Sarcoma. In: Pocket Radiation Oncology. 2nd. None, None.
Letters to the Editor
- Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105: e355-e357, 2020.
Patient Reviews
CV information above last modified November 06, 2024